Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | ubiquitin specific peptidase 1 | Starlite/ChEMBL | No references |
Homo sapiens | euchromatic histone-lysine N-methyltransferase 2 | Starlite/ChEMBL | No references |
Homo sapiens | SMAD family member 2 | Starlite/ChEMBL | No references |
Homo sapiens | bromodomain adjacent to zinc finger domain, 2B | Starlite/ChEMBL | No references |
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | MH2 domain containing protein | SMAD family member 2 | 467 aa | 405 aa | 31.6 % |
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | hypothetical protein | 0.0025 | 0.0241 | 0.1112 |
Echinococcus multilocularis | fetal alzheimer antigen, falz | 0.0027 | 0.0327 | 0.1541 |
Loa Loa (eye worm) | hypothetical protein | 0.0049 | 0.1148 | 0.1298 |
Schistosoma mansoni | methyl-cpg binding protein mbd | 0.0021 | 0.0079 | 0.0366 |
Echinococcus multilocularis | histone lysine N methyltransferase SETMAR | 0.0036 | 0.0657 | 0.3205 |
Schistosoma mansoni | histone-lysine n-methyltransferase setb1 | 0.0057 | 0.1426 | 0.6587 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.006 | 0.1559 | 0.1772 |
Trypanosoma cruzi | ISWI complex protein | 0.0018 | 0 | 0.5 |
Echinococcus granulosus | fetal alzheimer antigen falz | 0.0027 | 0.0327 | 0.1541 |
Trichomonas vaginalis | set domain proteins, putative | 0.0286 | 1 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.0018 | 0 | 0.5 |
Brugia malayi | PHD-finger family protein | 0.003 | 0.0434 | 0.0475 |
Schistosoma mansoni | bromodomain containing protein | 0.0076 | 0.2165 | 1 |
Brugia malayi | Pre-SET motif family protein | 0.0251 | 0.8702 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0019 | 0.0021 | 0.0099 |
Loa Loa (eye worm) | hypothetical protein | 0.0057 | 0.1426 | 0.1618 |
Brugia malayi | Pre-SET motif family protein | 0.0036 | 0.0657 | 0.0732 |
Schistosoma mansoni | acetyl-CoA C-acetyltransferase | 0.0027 | 0.0327 | 0.151 |
Echinococcus granulosus | 5'partial|histone lysine N methyltransferase SETDB2 | 0.0035 | 0.0607 | 0.2955 |
Schistosoma mansoni | histone-lysine n-methyltransferase setb1 | 0.0057 | 0.1426 | 0.6587 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0144 | 0.4698 | 0.5387 |
Plasmodium vivax | SET domain protein, putative | 0.0036 | 0.0657 | 0.5 |
Loa Loa (eye worm) | PHD-finger family protein | 0.0025 | 0.0241 | 0.0253 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.006 | 0.1559 | 0.1772 |
Brugia malayi | Bromodomain containing protein | 0.0046 | 0.1038 | 0.1171 |
Echinococcus multilocularis | histone lysine methyltransferase setb histone lysine methyltransferase eggless | 0.0057 | 0.1426 | 0.7087 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0043 | 0.0931 | 0.4589 |
Schistosoma mansoni | hypothetical protein | 0.0019 | 0.0021 | 0.0099 |
Loa Loa (eye worm) | hypothetical protein | 0.0041 | 0.0848 | 0.0952 |
Loa Loa (eye worm) | bromodomain containing protein | 0.0021 | 0.0107 | 0.0098 |
Schistosoma mansoni | histone-lysine n-methyltransferase suv9 | 0.0036 | 0.0657 | 0.3033 |
Echinococcus multilocularis | methyl CpG binding domain protein 2 | 0.0021 | 0.0079 | 0.0291 |
Loa Loa (eye worm) | hypothetical protein | 0.0085 | 0.2501 | 0.2857 |
Echinococcus granulosus | methyl CpG binding domain protein 2 | 0.0021 | 0.0079 | 0.0291 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.006 | 0.1559 | 0.1772 |
Echinococcus granulosus | histone lysine methyltransferase setb | 0.0057 | 0.1426 | 0.7087 |
Toxoplasma gondii | histone lysine methyltransferase SET/SUV39 | 0.0036 | 0.0657 | 0.5 |
Trypanosoma cruzi | ISWI complex protein | 0.0018 | 0 | 0.5 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0043 | 0.0931 | 0.4589 |
Schistosoma mansoni | zinc finger protein | 0.0024 | 0.0193 | 0.0891 |
Loa Loa (eye worm) | hypothetical protein | 0.0046 | 0.1041 | 0.1175 |
Schistosoma mansoni | hypothetical protein | 0.0041 | 0.0848 | 0.3914 |
Echinococcus multilocularis | zinc finger protein | 0.0024 | 0.0193 | 0.0866 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0041 | 0.0848 | 0.0952 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0072 | 0.2004 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0052 | 0.1234 | 0.1397 |
Brugia malayi | Bromodomain containing protein | 0.0091 | 0.2694 | 0.3079 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 0.1559 | 0.1772 |
Loa Loa (eye worm) | pre-SET domain-containing protein family protein | 0.0251 | 0.8702 | 1 |
Trypanosoma brucei | ISWI complex protein | 0.0018 | 0 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0019 | 0.0021 | 0.0099 |
Schistosoma mansoni | histone-lysine n-methyltransferase setb1 | 0.0036 | 0.0657 | 0.3033 |
Schistosoma mansoni | hypothetical protein | 0.0019 | 0.0021 | 0.0099 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0072 | 0.2004 | 1 |
Brugia malayi | MH2 domain containing protein | 0.0144 | 0.4698 | 0.5387 |
Schistosoma mansoni | methyl-cpg binding protein mbd | 0.0021 | 0.0079 | 0.0366 |
Echinococcus granulosus | zinc finger protein | 0.0024 | 0.0193 | 0.0866 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0144 | 0.4698 | 0.5387 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 2.8184 uM | PubChem BioAssay. Inhibitors of USP1/UAF1: Primary Screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 8.9125 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Potency (functional) | 11.2202 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404] | ChEMBL. | No reference |
Potency (functional) | 14.1254 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 19.9526 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of BAZ2B. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504391] | ChEMBL. | No reference |
Potency (functional) | 28.1838 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of JMJD2A-Tudor Domain. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504402] | ChEMBL. | No reference |
Potency (binding) | = 35.4813 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent). (Class of assay: confirmatory) [Related pubchem assays: 2158 (Confirmation qHTS Assay for Inhibitors of Cruzain), 2249 (Probe Development Summary of Promiscuous Inhibitors (Artifacts) of Cruzain), 2161 (qHTS Assay for Inhibitors of Papain: Counterscreen for Cruzain Assay), 1478 (qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent))] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.